<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104121">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810861</url>
  </required_header>
  <id_info>
    <org_study_id>B1851148</org_study_id>
    <nct_id>NCT01810861</nct_id>
  </id_info>
  <brief_title>Serotype Distribution and Antibiotic Sensitivity of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey: Multi-centered, Retrospective Laboratory Trial</brief_title>
  <official_title>Serotype Distribution and Antibiotic Sensitivity of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey: Multi-centered, Retrospective Laboratory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae
      that causes invasive diseases at children and adults in Turkey.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional observational study Descriptive analysis will be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Identification of S. pneumoniae serotype distribution</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of antibiotic susceptibility of the isolates</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pneumococcal Diseases</condition>
  <arm_group>
    <arm_group_label>Serotype distribution</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serotype distribution</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Serotype distribution</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, CSF and/or other sterile body areas (catheter, pleural fluid, parasynthesis fluid,
      pericardial fluid, synovial fluid, BAL)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pneumococcal isolates that are obtained from the blood, CSF and/or other sterile body
        areas (catheter, pleural fluid, parasynthesis fluid, pericardial fluid, synovial fluid,
        BAL) with the aim of routine laboratory diagnosis from the pediatric patients that are
        younger than 18 years old (â‰¤18), who are accepted to the pediatric clinic with the
        diagnosis of meningitides, bacteremia - sepsis or pneumonia, will be included in the
        trial.

        S.pneumoniae isolates that meet the inclusion criteria and that are obtained from the
        invasive clinical samples of the adult patients that are over 18 years old (&gt;18) and
        applied to the hospital are included in the trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Serotype distribution and antibiotic sensitivity of pneumococcal isolates that causes
        invasive pneumococcal diseases which are obtained from the blood, CSF, and/or all other
        sterile body areas (catheter, pleural fluid, parasynthesis fluid, pericardial fluid,
        synovial fluid, BAL) of the adults of 18 years of age or older with children that are
        younger than 18 years old at these centers and laboratories will be defined.

        Exclusion Criteria:

        Isolation of any other microorganism than pneumococcus at the same sample.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pfizer Oncology Clinical Trial Information Service</last_name>
    <phone>1-877-369-9753</phone>
    <email>PfizerCancerTrials@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Balcova</city>
        <state>Izmir</state>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gaziantep</city>
        <state>Turkiye</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <state>Turkiye</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kahramanmaras</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Samanpazari, Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Van</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851148&amp;StudyName=Serotype%20Distribution%20and%20Antibiotic%20Sensitivity%20of%20Streptococcus%20Pneumoniae%20That%20Causes%20Invasive%20Diseases%20at%20Children%20and%20Adults%20in%20Turkey%</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serotype distribution</keyword>
  <keyword>streptococcus pneumoniae</keyword>
  <keyword>pneumonia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
